[NFS-02] The emergence of a new era of gene therapy and regenerative medicine in Neurology

[NFS-02-1] 核酸医薬品による治療法の現状と展望

永田 哲也 (東京医科歯科大学病院 脳神経病態学（神経内科）分野)

In 2017, an antisense oligonucleotide, nusinersen, was approved as the first treatment for spinal muscular atrophy (SMA). Nusinersen avoids the blood-brain barrier by being injected directly into the cerebrospinal spinal fluid space, and it also eclipsed the existing paradigm of neurological therapeutics. In addition, positive results of a clinical trial of SMA gene therapy using a neurotropic adeno-associated virus (AAV) type 9 were also announced. In 2018, furthermore, transplantation treatment using iPS cells / ES cells against Parkinson's disease was about to begin as an actual clinical trial.
At this symposium, world-leading scientists will talk about gene therapy / regenerative medicine with new modalities designed to overcome intractable neurological diseases.

2018-Current
Research Associate Professor, Department of Neurology, Department of Neurology and Neurological Science, Tokyo Medical and Dental University
2014-2018
Research Senior Assistant Professor, Department of Neurology, Department of Neurology and Neurological Science, Tokyo Medical and Dental University
2009-2014
Section chief, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry
2008
Assistant Professor, Department of Neurology, Okayama University School of Medicine
2005-2008
Postdoctoral fellow, Department of Neurology/Center for Motor Neuron Biology and Disease, Columbia University
2003-2005
Assistant Professor, Department of Neurology, Okayama University School of Medicine
1999
Graduated from Tohoku University Graduate School
1994
Graduated from Tohoku University School of Medicine